-
Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
•
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being…
-
Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines
•
China-based Brii Biosciences Ltd (HKG: 2137) has announced its intention to acquire the intellectual property (IP) and other assets related to BRII-179 from its US partner VBI Vaccines, Inc. and certain of its subsidiaries (VBI), as well as its creditor K2 VBI Equity Trust, LLC and K2 HealthVentures LLC. Comprehensive…
-
Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
•
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218), an investigational small interfering ribonucleic acid (siRNA) therapy for chronic hepatitis B virus (HBV) infection. Phase II ENSURE Study Design and Initial FindingsThe active-controlled and randomized Phase II…
-
Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization
•
Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its US partner VBI Vaccines Inc. (OTCMKTS: VBIVQ) has commenced bankruptcy reorganization proceedings. Brii Bio has a history of licensing agreements with VBI, securing exclusive global rights to BRII-179 and Asia-Pacific rights to PreHevbri (excluding Japan)…
-
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy
•
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the appointment of Dr. Brian Alvin Johns as the firm’s Chief Scientific Officer (CSO), effective from January 3, 2024. In his new role, Dr. Johns will be responsible for overseeing the company’s discovery programs and charting…
-
Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs
•
Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition of US anti-infectives specialist Qpex Biopharma Inc., for USD 100 million upfront and an additional USD 40 million based on certain development and regulatory milestones. This deal has significant implications for China-based biotech Brii Biosciences…
-
Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
•
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I clinical study assessing the safety, tolerability, and pharmacokinetics of its BRII-297 in healthy subjects in Australia. This marks a significant step in the development of the drug candidate, which is being closely watched for its…
-
Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778
•
China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I clinical studies assessing its long-acting BRII-732 and BRII-778, both being developed to treat HIV infection, in healthy subjects in the US. The results showed that both BRII-732 and BRII-778 produced good safety and tolerability profiles…
-
Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296
•
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I study for its long-acting, single-injection therapy for postpartum depression (PPD), BRII-296. The open-label, single ascending dose Phase I study assessed the safety, tolerability, and pharmacokinetics (PK) of BRII-296 as a single-injection treatment option for PPD…
-
Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1
•
China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab has demonstrated sustained neutralizing activity against the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants. Study ResultsLive virus neutralization experiments conducted in the US showed that 14 days after dosing, the total plasma concentration of the combination…
-
Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China
•
China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International Trade Co., Ltd to accelerate the commercialization of its anti-COVID-19 antibody cocktail, BRII-196 plus BRII-198 (amubarvimab/romlusevimab), in China. The collaboration will focus on warehousing, channel distribution, regional access, and other innovative aspects, though financial details…
